Developer docs
API playgroundTry for free, no card

Search company profiles

Axoltis Pharma

Full company profile

uuid000f75x

Namestring
Axoltis Pharma
Legal namestring
Axoltis Pharma
Websiteurl
axoltis.com
Company typeenum
Private
Founded yearint
2003
Descriptiontext

Axoltis Pharma is a clinical-stage French biotechnology company developing first-in-class therapeutics for degenerative and traumatic neurological disorders with high unmet medical needs. The company's lead asset, NX210c, is a 12 amino-acid synthetic peptide (a Thrombospondin Repeat analog) inspired by SCO-spondin, a multifunctional glycoprotein essential in neurogenesis. NX210c is designed around a single mechanistic thesis: that blood-brain barrier (BBB) dysfunction is a central driver of neurodegeneration across multiple diseases. The molecule combines three properties — BBB restoration, neuroprotection against glutamate excitotoxicity and oxidative stress, and enhancement of synaptic neurotransmission — that together aim to halt disease progression rather than address a single downstream symptom.

Axoltis is currently executing the SEALS Phase 2 clinical trial, evaluating NX210c in 82 ALS patients across 16 clinical centers in France, with topline efficacy and tolerability results expected in Q2 2026. The clinical program is anchored by Orphan Drug Designation granted by both the FDA and EMA for ALS, and supported by 7 fully owned patent families including composition of matter granted in the EU, USA, and Japan. The pipeline extends beyond ALS to Multiple Sclerosis (with active in silico QSP modeling via InSilicoTrials Technologies), Alzheimer's Disease, Parkinson's Disease, and Spinal Cord Injury, all sharing BBB dysfunction as the underlying pathology. The company has built a scientific and operational network spanning Trinity College Dublin, University of Eastern Finland, CNRS, Texas A&M University, the CRO Neuro-Sys, and patient associations (ARSLA, Fondation SLA Suisse, Act 4 ALS).

The company has no commercial revenue. Its revenue model is future one-time licensing or commercialization of NX210c upon regulatory approval; until then, it is funded by dilutive equity (€18 million Series A closed December 2025, led by Cenitz and FIDAT Ventures) and public/private support (Bpifrance, Lyonbiopole, regional Auvergne-Rhône-Alpes programs). The team is small (1-10 employees), operating from Clermont-Ferrand (headquarters) and a Lyon secondary office in the Bioparc Laennec. Customer-facing activity is limited to clinical trial conduct, with partnership discussions with global pharmaceutical companies identified as an explicit use of Series A proceeds.

Short descriptiontext

Axoltis Pharma is a clinical-stage French biotech developing NX210c, a synthetic peptide that restores blood-brain barrier integrity, for ALS and other neurodegenerative diseases, currently in Phase 2 trials with results expected Q2 2026.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLyon, France
HQ citystring
Lyon
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
neurodegenerative drug development, peptide therapeutics, ALS treatment, blood-brain barrier repair, central nervous system disorders
Industry1 code
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Neurological Pharmaceuticals
Social media profiles1 record
Revenue model1 record
1Pharmaceutical Drug Development
TypeOne Time License
Description

Pre-revenue biotech company developing NX210c drug candidate through clinical trials. Revenue will be generated through drug commercialization upon regulatory approval.

axoltis.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Axoltis Pharma is a clinical-stage French biotech company developing NX210c, a 12-amino-acid synthetic peptide drug candidate inspired by SCO-spondin, designed to restore blood-brain barrier integrity, provide neuroprotection, and enhance neurotransmission for the treatment of neurodegenerative and traumatic neurological disorders. The lead indication is Amyotrophic Lateral Sclerosis (ALS), with Phase 2 SEALS clinical trial topline results expected Q2 2026.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Phase 2 SEALS trial evaluating efficacy and tolerability in 82 ALS patients with results expected Q2 2026
+2 more records
Product overview1 text field

Axoltis Pharma operates as a clinical-stage biotech company with a single lead drug candidate, NX210c, currently in Phase 2 development. The company is not organized as a platform-plus-modules architecture; rather, it is focused exclusively on advancing NX210c through clinical development for neurodegenerative diseases. The product pipeline includes Multiple Sclerosis and other CNS disorders as potential future indications, with the core product being an innovative peptide therapeutic targeting blood-brain barrier integrity.

Product and service1 record
1NX210c
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
1Lyonbiopole
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Cluster supporting biotechnology and medtech companies in the Lyon area.

axoltis.com
Strategic tierSupportingTypeTechnology or Integration
Description

CRO specializing in neurodegenerative disorders; Dr. Noelle Callizot is CSO and co-founder.

Strategic tierSupportingTypeTechnology or Integration
Description

Technology partner for in silico QSP simulation and modeling for Multiple Sclerosis indication.

Strategic tierSupportingTypeTechnology or Integration
Description

Scientific partner with Prof. Matthew Campbell providing expertise in blood-brain barrier research. Prof. Campbell serves on the Scientific Advisory Board.

Strategic tierSupportingTypeTechnology or Integration
Description

Academic research partner in neuroscience and blood-brain barrier studies.

6CNRS
Strategic tierSupportingTypeTechnology or Integration
Description

French National Center for Scientific Research - academic partner in research collaborations.

axoltis.com
Strategic tierSupportingTypeTechnology or Integration
Description

Academic research partner in neuroscience and biotechnology.

8ARSLA
Strategic tierSupportingTypeOthers
Description

French patient association supporting ALS patients and research.

axoltis.com
9Act 4 ALS
Strategic tierSupportingTypeOthers
Description

Patient advocacy organization for ALS research and patient support.

axoltis.com
Strategic tierSupportingTypeOthers
Description

Swiss foundation supporting ALS research and patient advocacy.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Alector is a clinical-stage immuno-neurology biotech developing monoclonal antibodies for neurodegenerative diseases including frontotemporal dementia and Alzheimer's. It is an emerging peer in CNS drug development with a similar late-clinical-stage risk profile and large-pharma partnership model (with AbbVie).

TypeEmerging player
Description

Denali is a clinical-stage biotech developing BBB-penetrant therapeutics (including enzyme and protein degraders) for ALS, Parkinson's, and other neurodegenerative diseases. It is an emerging peer whose BBB-trafficking platform is directly adjacent to Axoltis's BBB-restoration thesis.

TypeEmerging player
Description

QurAlis is an emerging US-based precision medicine biotech developing genetically targeted therapies for ALS, including splice-modulating and TDP-43 programs. It is an emerging ALS peer with a different (genetic) approach but overlapping patient population and ODD strategy.

TypeEmerging player
Description

Helixmith is a clinical-stage biotech developing Engensis (VM202), a plasmid DNA therapy, for ALS and other neurodegenerative indications. It is an emerging peer in orphan ALS drug development with a comparable small-cap, single-asset profile.

TypeDirect peer
Description

Cytokinetics is a clinical-stage biopharmaceutical company developing novel muscle activators for ALS (e.g., reldesemtiv) and other diseases of impaired muscle function. It is a direct peer in the orphan ALS therapeutics space, with comparable single-indication focus, similar regulatory pathway (ODD), and overlapping clinical centers in the US/EU.

TypeBroad incumbent
Description

Biogen is a large neuroscience-focused biopharma with an approved ALS therapy (Qalsody/tofersen) and broad CNS pipeline. It is a broad incumbent in the same disease space and a likely potential acquirer or partner for late-stage ALS assets like NX210c.

TypeDirect peer
Description

Clene is a clinical-stage nanomedicine company developing CNM-Au8, a gold nanocatalyst, for ALS and other neurodegenerative diseases. It is a direct peer in orphan ALS drug development with a similar capital structure and a single lead asset advancing through Phase 2/3.

TypeDirect peer
Description

BrainStorm is a clinical-stage biotech developing NurOwn, an autologous cell therapy for ALS. It is a direct peer competing in the same orphan ALS market with a different modality (cell therapy vs. peptide), facing similar regulatory and capital intensity challenges.

9AB Science
TypeDirect peer
Description

AB Science is a French clinical-stage pharma company developing masitinib for ALS and other neurodegenerative/inflammatory conditions. It is a directly comparable peer — small French sponsor, orphan CNS indication, late-stage pivotal trials, similar capital-constrained profile.

TypeBroad incumbent
Description

Ionis is a leading antisense oligonucleotide platform company with multiple ALS programs (in partnership with Biogen). It is a broad incumbent competing in CNS, including for ALS patients, and a potential partner for peptide-based BBB targets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Axoltis Pharma

Neurological Pharmaceuticalsaxoltis.com

Axoltis Pharma is a clinical-stage French biotech developing NX210c, a synthetic peptide that restores blood-brain barrier integrity, for ALS and other neurodegenerative diseases, currently in Phase 2 trials with results expected Q2 2026.

What Axoltis Pharma does

Axoltis Pharma is a clinical-stage French biotechnology company developing first-in-class therapeutics for degenerative and traumatic neurological disorders with high unmet medical needs. The company's lead asset, NX210c, is a 12 amino-acid synthetic peptide (a Thrombospondin Repeat analog) inspired by SCO-spondin, a multifunctional glycoprotein essential in neurogenesis. NX210c is designed around a single mechanistic thesis: that blood-brain barrier (BBB) dysfunction is a central driver of neurodegeneration across multiple diseases. The molecule combines three properties — BBB restoration, neuroprotection against glutamate excitotoxicity and oxidative stress, and enhancement of synaptic neurotransmission — that together aim to halt disease progression rather than address a single downstream symptom.

Axoltis is currently executing the SEALS Phase 2 clinical trial, evaluating NX210c in 82 ALS patients across 16 clinical centers in France, with topline efficacy and tolerability results expected in Q2 2026. The clinical program is anchored by Orphan Drug Designation granted by both the FDA and EMA for ALS, and supported by 7 fully owned patent families including composition of matter granted in the EU, USA, and Japan. The pipeline extends beyond ALS to Multiple Sclerosis (with active in silico QSP modeling via InSilicoTrials Technologies), Alzheimer's Disease, Parkinson's Disease, and Spinal Cord Injury, all sharing BBB dysfunction as the underlying pathology. The company has built a scientific and operational network spanning Trinity College Dublin, University of Eastern Finland, CNRS, Texas A&M University, the CRO Neuro-Sys, and patient associations (ARSLA, Fondation SLA Suisse, Act 4 ALS).

The company has no commercial revenue. Its revenue model is future one-time licensing or commercialization of NX210c upon regulatory approval; until then, it is funded by dilutive equity (€18 million Series A closed December 2025, led by Cenitz and FIDAT Ventures) and public/private support (Bpifrance, Lyonbiopole, regional Auvergne-Rhône-Alpes programs). The team is small (1-10 employees), operating from Clermont-Ferrand (headquarters) and a Lyon secondary office in the Bioparc Laennec. Customer-facing activity is limited to clinical trial conduct, with partnership discussions with global pharmaceutical companies identified as an explicit use of Series A proceeds.

Axoltis Pharma firmographics

Firmographics
Name
Axoltis Pharma
Legal name
Axoltis Pharma
Website
https://axoltis.com
Company type
Private
Founded year
2003
Operating status
Operating
Headcount range
11–50 employees
Short description
Axoltis Pharma is a clinical-stage French biotech developing NX210c, a synthetic peptide that restores blood-brain barrier integrity, for ALS and other neurodegenerative diseases, currently in Phase 2 trials with results expected Q2 2026.
Ownership category
akta.pro rank

Axoltis Pharma industry classification

Industry
Product category
Neurological Pharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals

Keywords

  • Neurodegenerative drug development
  • Peptide therapeutics
  • ALS treatment
  • Blood-brain barrier repair
  • Central nervous system disorders

Where Axoltis Pharma is headquartered

Location

Headquarters

HQ city
Lyon
HQ country
France
HQ region
Europe

Offices2 records

Markets served

Axoltis Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Others

Revenue model

  1. Pharmaceutical Drug Development: Pre-revenue biotech company developing NX210c drug candidate through clinical trials. Revenue will be generated through drug commercialization upon regulatory approval.

Distribution channels1 record

Marketing channels2 records

Axoltis Pharma product offering

Product offering

Core offering

Axoltis Pharma is a clinical-stage French biotech company developing NX210c, a 12-amino-acid synthetic peptide drug candidate inspired by SCO-spondin, designed to restore blood-brain barrier integrity, provide neuroprotection, and enhance neurotransmission for the treatment of neurodegenerative and traumatic neurological disorders. The lead indication is Amyotrophic Lateral Sclerosis (ALS), with Phase 2 SEALS clinical trial topline results expected Q2 2026.

Product overview

Axoltis Pharma operates as a clinical-stage biotech company with a single lead drug candidate, NX210c, currently in Phase 2 development. The company is not organized as a platform-plus-modules architecture; rather, it is focused exclusively on advancing NX210c through clinical development for neurodegenerative diseases. The product pipeline includes Multiple Sclerosis and other CNS disorders as potential future indications, with the core product being an innovative peptide therapeutic targeting blood-brain barrier integrity.

Differentiator

Problem solved

Functional benefit

Products and services

  • NX210c

Quantifiable outcome

  • Phase 2 SEALS trial evaluating efficacy and tolerability in 82 ALS patients with results expected Q2 2026
  • +2 more outcomes

Companies that use Axoltis Pharma

Customer profile

Segments2 records

Ideal customer profiles2 records

Axoltis Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Axoltis Pharma partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered supporting.

  • LyonbiopolesupportingStrategic or Co-development PartnerCluster supporting biotechnology and medtech companies in the Lyon area.
  • Neuro-SyssupportingTechnology or IntegrationCRO specializing in neurodegenerative disorders; Dr. Noelle Callizot is CSO and co-founder.
  • InSilicoTrials TechnologiessupportingTechnology or IntegrationTechnology partner for in silico QSP simulation and modeling for Multiple Sclerosis indication.
  • Trinity College DublinsupportingTechnology or IntegrationScientific partner with Prof. Matthew Campbell providing expertise in blood-brain barrier research. Prof. Campbell serves on the Scientific Advisory Board.
  • University of Eastern FinlandsupportingTechnology or IntegrationAcademic research partner in neuroscience and blood-brain barrier studies.
  • CNRSsupportingTechnology or IntegrationFrench National Center for Scientific Research - academic partner in research collaborations.
  • Texas A&M UniversitysupportingTechnology or IntegrationAcademic research partner in neuroscience and biotechnology.
  • ARSLAsupportingOthersFrench patient association supporting ALS patients and research.
  • Act 4 ALSsupportingOthersPatient advocacy organization for ALS research and patient support.
  • Fondation SLA SuissesupportingOthersSwiss foundation supporting ALS research and patient advocacy.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Axoltis Pharma competitors and assessment

Company assessment

Emerging players

  • Alector: Alector is a clinical-stage immuno-neurology biotech developing monoclonal antibodies for neurodegenerative diseases including frontotemporal dementia and Alzheimer's. It is an emerging peer in CNS drug development with a similar late-clinical-stage risk profile and large-pharma partnership model (with AbbVie).
  • Denali Therapeutics: Denali is a clinical-stage biotech developing BBB-penetrant therapeutics (including enzyme and protein degraders) for ALS, Parkinson's, and other neurodegenerative diseases. It is an emerging peer whose BBB-trafficking platform is directly adjacent to Axoltis's BBB-restoration thesis.
  • QurAlis: QurAlis is an emerging US-based precision medicine biotech developing genetically targeted therapies for ALS, including splice-modulating and TDP-43 programs. It is an emerging ALS peer with a different (genetic) approach but overlapping patient population and ODD strategy.
  • Helixmith: Helixmith is a clinical-stage biotech developing Engensis (VM202), a plasmid DNA therapy, for ALS and other neurodegenerative indications. It is an emerging peer in orphan ALS drug development with a comparable small-cap, single-asset profile.

Direct peers

  • Cytokinetics: Cytokinetics is a clinical-stage biopharmaceutical company developing novel muscle activators for ALS (e.g., reldesemtiv) and other diseases of impaired muscle function. It is a direct peer in the orphan ALS therapeutics space, with comparable single-indication focus, similar regulatory pathway (ODD), and overlapping clinical centers in the US/EU.
  • Clene Nanomedicine: Clene is a clinical-stage nanomedicine company developing CNM-Au8, a gold nanocatalyst, for ALS and other neurodegenerative diseases. It is a direct peer in orphan ALS drug development with a similar capital structure and a single lead asset advancing through Phase 2/3.
  • BrainStorm Cell Therapeutics: BrainStorm is a clinical-stage biotech developing NurOwn, an autologous cell therapy for ALS. It is a direct peer competing in the same orphan ALS market with a different modality (cell therapy vs. peptide), facing similar regulatory and capital intensity challenges.
  • AB Science: AB Science is a French clinical-stage pharma company developing masitinib for ALS and other neurodegenerative/inflammatory conditions. It is a directly comparable peer — small French sponsor, orphan CNS indication, late-stage pivotal trials, similar capital-constrained profile.

Broad incumbents

  • Biogen: Biogen is a large neuroscience-focused biopharma with an approved ALS therapy (Qalsody/tofersen) and broad CNS pipeline. It is a broad incumbent in the same disease space and a likely potential acquirer or partner for late-stage ALS assets like NX210c.
  • Ionis Pharmaceuticals: Ionis is a leading antisense oligonucleotide platform company with multiple ALS programs (in partnership with Biogen). It is a broad incumbent competing in CNS, including for ALS patients, and a potential partner for peptide-based BBB targets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Axoltis Pharma social profiles

Digital presence

Axoltis Pharma compliance and trust

Trust signal

Compliance1 record

Axoltis Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Axoltis Pharma leadership team

Management profile

Number of profiles

Profiles10 records

Axoltis Pharma funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Axoltis Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Axoltis Pharma

What does Axoltis Pharma do?

Axoltis Pharma is a clinical-stage French biotech company developing NX210c, a 12-amino-acid synthetic peptide drug candidate inspired by SCO-spondin, designed to restore blood-brain barrier integrity, provide neuroprotection, and enhance neurotransmission for the treatment of neurodegenerative and traumatic neurological disorders. The lead indication is Amyotrophic Lateral Sclerosis (ALS), with Phase 2 SEALS clinical trial topline results expected Q2 2026.

Is Axoltis Pharma a public or private company?

Axoltis Pharma is a private company. It is classified as venture growth investor backed and is currently operating.

When was Axoltis Pharma founded?

Axoltis Pharma was founded in 2003. It employs 11 to 50 people.

Where is Axoltis Pharma based?

Axoltis Pharma is headquartered in Lyon, France, in the Europe region.

How does Axoltis Pharma make money?

One revenue line is on record: pharmaceutical Drug Development.

Who are Axoltis Pharma's main competitors?

Emerging players on record are Alector, Denali Therapeutics, QurAlis and Helixmith. Direct peers are Cytokinetics, Clene Nanomedicine, BrainStorm Cell Therapeutics and AB Science. Broad incumbents are Biogen and Ionis Pharmaceuticals.

Does Axoltis Pharma have an API?

No public API is recorded for Axoltis Pharma.

What industry is Axoltis Pharma in?

Axoltis Pharma's product category is Neurological Pharmaceuticals. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Pharma LetterAxoltis Pharma presents further Phase II data on NX210cAxoltis Pharma presented additional data and analyses from its Phase II trial of NX210c in ALS patients at Neuroscience 2026 in Washington DC. The findings build on initial results announced on September 15, 2026.PharmaTimesAxoltis reports positive phase 2 data for NX210cAxoltis reported topline data from its phase 2 SEALS trial of NX210c in ALS, showing reduced decline in ALSFRS-R and motor function benefits versus placebo. The drug did not meet its primary endpoint but showed positive trends in secondary measures and BBB target engagement. Axoltis plans further analyses and will present results at Neuroscience 2026.European BiotechnologyNovartis drops TREM2 antibody in ALS after Phase 2 missNovartis's ASTRALS failed its Phase 2 trial of the TREM2 antibody VHB937 in ALS, with no numerical data released. The trial enrolled 251 patients and measured survival without ventilation and functional decline. Detailed findings are due at the ALS symposium in Amsterdam on Dec. 9-11.Biotech FinancesALS: AXOLTIS PHARMA MAINTAINS ITS TIMELINE FOR A PHASE 2b/3Axoltis Pharma released SEALS data for its ALS candidate NX210c, with the primary endpoint not met. CEO Yann Godfrin said the data is sufficient to proceed, and investor confidence remains with visibility extended to the end of 2027.Clinical Trials ArenaAxoltis’ Phase II ALS trial fails; company points to exploratory endpointsAxoltis Pharma's Phase II ALS trial of NX210c failed to meet its primary endpoint, showing no significant benefit in neurofilament light chain or albumin quotient after six weeks. However, exploratory data showed consistent positive trends, including a 41% reduction in ALSFRS-R slope decline for the 5mg/kg arm. The company plans further analyses and will present data at Neuroscience 2026.European BiotechnologyAxoltis ALS drug misses Phase 2 endpointAxoltis Pharma's NX210c missed its primary endpoint in a Phase 2 ALS trial, but post-hoc analyses showed slower functional decline. The 5 mg/kg dose reduced ALSFRS-R decline by 51% versus placebo at week 10. Axoltis plans further development after analyzing 10-month follow-up.FierceBiotechAxoltis misses the mark in phase 2 ALS study, but will persevere with the synthetic peptideAxoltis Pharma's phase 2 ALS trial for NX210c missed its primary endpoint, but showed significant reductions in blood claudin-5 and motor function improvements. The company plans to advance the synthetic peptide to next stages of clinical development.The French Tech JournalFrench Tech Funding Wire December 8: VC Deals Fall; TechBio Rises; €175.35M Raised In 18 RoundsFrench tech companies raised a total of €175.35 million across 18 funding rounds during the week of December 5, spanning sectors including AI/software (€75.75M), medtech/health (€46.90M), fintech (€22.70M), deeptech/industrial (€20M), and agrifood (€10M). Notable deals include Gradium's €60M seed round to commercialize Kyutai's speech-to-speech AI models, Axoltis Pharma's €18M Series A for ALS clinical trials, and Spark Cleantech's €30M raise for decarbonization technology. The article provides context that French VC deal counts are declining in 2025, mirroring global trends, while highlighting TechBio as a rising sector in France.Pulse 2.0Axoltis Pharma: €18 Million Closed To Advance Phase 2 ALS Candidate NX210cAxoltis Pharma has closed an €18 million Series A round to advance NX210c, its Phase 2 candidate for Amyotrophic Lateral Sclerosis (ALS), with the raise structured in two tranches and the second contingent on Phase 2 SEALS trial results expected in Q2 2026. FIDAT Ventures and Cenitz co-led the round, joined by Capital Cell crowdfunding participants and multiple legacy investors, while Agile Capital Market advised the transaction. The funding will support continued clinical development of NX210c across 16 sites in an 82-patient trial and explore applicability in additional neurological indications.